BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 17702723)

  • 1. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.
    Walsh M; James M; Jayne D; Tonelli M; Manns BJ; Hemmelgarn BR
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):968-75. PubMed ID: 17702723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
    Rovin BH; Parikh SV; Hebert LA; Chan TM; Mok CC; Ginzler EM; Hooi LS; Brunetta P; Maciuca R; Solomons N
    Clin J Am Soc Nephrol; 2013 Jan; 8(1):147-53. PubMed ID: 22879439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.
    Liu LL; Jiang Y; Wang LN; Yao L; Li ZL
    Drugs; 2012 Jul; 72(11):1521-33. PubMed ID: 22818016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
    Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
    N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
    Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
    N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
    Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
    Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for lupus nephritis.
    Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
    Ginzler EM; Wofsy D; Isenberg D; Gordon C; Lisk L; Dooley MA;
    Arthritis Rheum; 2010 Jan; 62(1):211-21. PubMed ID: 20039429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
    Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
    Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil.
    Lau KK; Ault BH; Jones DP; Butani L
    J Pediatr Health Care; 2008; 22(5):282-8. PubMed ID: 18761229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mycophenolate mofetil for the treatment of lupus nephritis. The case of lupus nephritis--class IV according to WHO--treated with mycophenolate mofetil].
    Suszek D; Wielosz E; Majdan M
    Ann Acad Med Stetin; 2010; 56 Suppl 1():91-4. PubMed ID: 21365951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.
    Kamanamool N; McEvoy M; Attia J; Ingsathit A; Ngamjanyaporn P; Thakkinstian A
    Medicine (Baltimore); 2010 Jul; 89(4):227-235. PubMed ID: 20616662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
    Dooley MA; Jayne D; Ginzler EM; Isenberg D; Olsen NJ; Wofsy D; Eitner F; Appel GB; Contreras G; Lisk L; Solomons N;
    N Engl J Med; 2011 Nov; 365(20):1886-95. PubMed ID: 22087680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Jones RB; Walsh M; Smith KG
    Curr Opin Rheumatol; 2009 May; 21(3):256-61. PubMed ID: 19399995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mycophenolate mofetil in lupus nephritis].
    Alvarez L; Rivera F; Gil CM; Jiménez del Cerro LA; Olivares J
    Nefrologia; 2002; 22(1):24-32. PubMed ID: 11987681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil in lupus nephritis.
    Ginzler EM; Aranow C
    Lupus; 2005; 14(1):59-64. PubMed ID: 15732290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
    Lanata CM; Mahmood T; Fine DM; Petri M
    Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
    Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: Outcomes at a tertiary care centre in Lahore, Pakistan.
    Saeed MA; Khan A; Naeem F; Ahmad NM
    J Pak Med Assoc; 2024 May; 74(5):868-873. PubMed ID: 38783432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.